Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Regeneron Pharmaceuticals Inc (REGN) vs Direxion Daily Semiconductor Bear 3X Shares (SOXS) Price & Performance

Regeneron Pharmaceuticals IncTrade
Direxion Daily Semiconductor Bear 3X SharesTrade

Price performance (Past 24H)

Key statistics

Regeneron Pharmaceuticals Inc vs Direxion Daily Semiconductor Bear 3X Shares — how do they compare? Regeneron Pharmaceuticals Inc trades at $745.88 (market cap $76.14B), while Direxion Daily Semiconductor Bear 3X Shares trades at $34.56 (market cap $1.96B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 38.8× Direxion Daily Semiconductor Bear 3X Shares's market cap, and Regeneron Pharmaceuticals Inc pays a 0.51% dividend while Direxion Daily Semiconductor Bear 3X Shares pays none. Which is the better fit depends on your goals — on Pluang, investors hold Regeneron Pharmaceuticals Inc for 107 Days and Direxion Daily Semiconductor Bear 3X Shares for 11 Days on average.

REGNSOXS
Market Cap
$76.14B$1.96B
Volume
500,239113,512,541
Sector
HealthLeveraged / Inverse
52-Week High
$852.03$988.00
52-Week Low
$557.73$29.62
Typical Hold Time
107 Days11 Days
Enterprise Value
$70.85B—
Dividend Yield
0.51%—

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Regeneron Pharmaceuticals Inc

Regeneron Pharmaceuticals (REGN) trades at $739.28, down 0.38% on the day, with a bearish technical signal and neutral oscillators. The company shows strong fundamentals with a P/E of 18.3, net income margin of 27.86%, and consistent earnings beats in recent quarters. Recent news highlights a major $8 billion immunology alliance expansion with Sanofi, including a $1 billion upfront payment, reinforcing its pipeline strength and long-term growth prospects.

The outlook remains positive driven by robust profitability, strategic collaborations, and a bullish analyst consensus with a $849.84 price target. Key risks include competitive pressures in key drug markets and reliance on successful clinical trial outcomes. Institutional sentiment is strong with no sell ratings, supporting a favorable risk-reward profile for investors seeking exposure to biopharmaceutical innovation.

Direxion Daily Semiconductor Bear 3X Shares

SOXS, a leveraged inverse ETF tracking the semiconductor sector, trades at $34.12, up 11.34% over 24 hours amid recent semiconductor stock weakness. Technical indicators are bearish overall, with moving averages signaling sell pressure, while oscillators are neutral. The fund executed a 1:10 stock split in July 2026 and has a dividend scheduled for September 2026. News highlights focus on volatility and tactical use, with articles noting surges during chip sell-offs.

The outlook for SOXS remains highly speculative, suitable only for short-term tactical trades due to its leveraged inverse structure and extreme volatility. Key risks include rapid erosion from semiconductor sector rebounds and structural decay. Investors should avoid long-term holdings, as persistent AI demand could trigger sharp losses.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

REGN
98% Buy2% Sell
Avg holding period · 107 Days
SOXS
57% Buy43% Sell
Avg holding period · 11 Days

About Regeneron Pharmaceuticals Inc

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases

Read more on REGN →

About Direxion Daily Semiconductor Bear 3X Shares

SOXS is a leveraged ETF that seeks daily investment results corresponding to 300% of the inverse (opposite) of the daily performance of the ICE Semiconductor Index. It is designed as a tactical tool for experienced traders to take a bearish (short) position on the semiconductor sector. Due to the effects of compounding and leverage, SOXS is intended to be held for a single day and is not suitable for long-term investment.

Read more on SOXS →